Anthera Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the development and commercialization of products to treat serious
and life-threatening diseases. The company’s product pipeline includes two
phase III product candidates. The first, Blisibimod, is currently being studied
for the treatment of lupus, a chronic disease that causes a patient’s immune
system to attack his or her own tissues and organs. The second, Sollpura™, is
currently being studied as a novel pancreatic enzyme replacement therapy for
the treatment of cystic fibrosis and related diseases.
In recent months, Anthera made major strides toward the
eventual commercialization of these two groundbreaking drug candidates. In
March, the company secured a research award of up to $3 million from Cystic
Fibrosis Foundation Therapeutics, Inc. to support the manufacturing and clinical
development of Sollpura.
“Support from Cystic Fibrosis Foundation Therapeutics speaks
to the importance of developing [Sollpura] and the organization’s extensive
clinical trials network will be indispensable as we advance this therapy,” Paul
F. Truex, president and chief executive officer of Anthera, stated in a news
release.
Earlier this month, the company made significant progress in
the development of Blisibimod by reaching the target enrollment goal for its
CHABLIS-SC1 phase III clinical trial. The results from this study, which are
expected to be available in the second half of 2016, are anticipated to support
the eventual market approval of Blisibimod for the treatment of lupus.
“Reaching our enrollment target for CHABLIS-SC1 ahead of
schedule is an important accomplishment,” stated Dr. Colin Hislop, chief
medical officer of Anthera. “The accelerated pace speaks to the importance of
patient identification and selection in lupus treatment.”
When commercialized, these two products could provide
Anthera with a strong platform to realize considerable growth within the
biopharmaceutical industry. According to the Lupus Foundation of America, an
estimated 1.5 million Americans, and at least five million people worldwide,
suffer from some form of Lupus. Likewise, according to the Cystic Fibrosis
Foundation, an estimated 30,000 Americans, and approximately 70,000 people
worldwide, suffer from cystic fibrosis.
For prospective investors, Anthera’s continued progress
toward commercialization of its two unique drug candidates makes the company an
intriguing investment opportunity in the months to come.
For more information, visit www.anthera.com
About
MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
